Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 12

1.

Escape from HER-family tyrosine kinase inhibitor therapy by the kinase-inactive HER3.

Sergina NV, Rausch M, Wang D, Blair J, Hann B, Shokat KM, Moasser MM.

Nature. 2007 Jan 25;445(7126):437-41. Epub 2007 Jan 7.

PMID:
17206155
[PubMed - indexed for MEDLINE]
Free PMC Article
2.

Targeting HER proteins in cancer therapy and the role of the non-target HER3.

Hsieh AC, Moasser MM.

Br J Cancer. 2007 Aug 20;97(4):453-7. Epub 2007 Jul 31. Review.

PMID:
17667926
[PubMed - indexed for MEDLINE]
Free PMC Article
3.

Role of HER2/HER3 co-receptor in breast carcinogenesis.

Way TD, Lin JK.

Future Oncol. 2005 Dec;1(6):841-9. Review.

PMID:
16556064
[PubMed - indexed for MEDLINE]
4.

The upgraded role of HER3 and HER4 receptors in breast cancer.

Koutras AK, Fountzilas G, Kalogeras KT, Starakis I, Iconomou G, Kalofonos HP.

Crit Rev Oncol Hematol. 2010 May;74(2):73-8. doi: 10.1016/j.critrevonc.2009.04.011. Epub 2009 May 30. Review.

PMID:
19481955
[PubMed - indexed for MEDLINE]
5.

ERBB3/HER3 and ERBB2/HER2 duet in mammary development and breast cancer.

Stern DF.

J Mammary Gland Biol Neoplasia. 2008 Jun;13(2):215-23. doi: 10.1007/s10911-008-9083-7. Epub 2008 May 3. Review.

PMID:
18454306
[PubMed - indexed for MEDLINE]
6.

Epidermal growth factor receptor/HER2/insulin-like growth factor receptor signalling and oestrogen receptor activity in clinical breast cancer.

Gee JM, Robertson JF, Gutteridge E, Ellis IO, Pinder SE, Rubini M, Nicholson RI.

Endocr Relat Cancer. 2005 Jul;12 Suppl 1:S99-S111. Review.

PMID:
16113104
[PubMed - indexed for MEDLINE]
Free Article
7.

The achilles heel of ErbB-2/HER2: regulation by the Hsp90 chaperone machine and potential for pharmacological intervention.

Citri A, Kochupurakkal BS, Yarden Y.

Cell Cycle. 2004 Jan;3(1):51-60. Review.

PMID:
14657666
[PubMed - indexed for MEDLINE]
Free Article
8.

The role of HER3, the unpretentious member of the HER family, in cancer biology and cancer therapeutics.

Amin DN, Campbell MR, Moasser MM.

Semin Cell Dev Biol. 2010 Dec;21(9):944-50. doi: 10.1016/j.semcdb.2010.08.007. Epub 2010 Sep 9. Review.

PMID:
20816829
[PubMed - indexed for MEDLINE]
Free PMC Article
9.

A pan-HER approach for cancer therapy: background, current status and future development.

Huang Z, Brdlik C, Jin P, Shepard HM.

Expert Opin Biol Ther. 2009 Jan;9(1):97-110. doi: 10.1517/14712590802630427 . Review.

PMID:
19063696
[PubMed - indexed for MEDLINE]
10.

Investigational therapies targeting the ErbB (EGFR, HER2, HER3, HER4) family in GI cancers.

Desai MD, Saroya BS, Lockhart AC.

Expert Opin Investig Drugs. 2013 Mar;22(3):341-56. doi: 10.1517/13543784.2013.761972. Epub 2013 Jan 15. Review.

PMID:
23316969
[PubMed - indexed for MEDLINE]
11.

HER2 therapy. HER2 (ERBB2): functional diversity from structurally conserved building blocks.

Landgraf R.

Breast Cancer Res. 2007;9(1):202. Review.

PMID:
17274834
[PubMed - indexed for MEDLINE]
Free PMC Article
12.

HER-2-directed, small-molecule antagonists.

Arkin M, Moasser MM.

Curr Opin Investig Drugs. 2008 Dec;9(12):1264-76. Review.

PMID:
19037833
[PubMed - indexed for MEDLINE]
Free PMC Article

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk